key: cord-0983346-44c62200
authors: Salerno, Michael; Kwong, Raymond
title: CMR in the era of COVID-19: Evaluation of Myocarditis in the Subacute Phase
date: 2020-07-03
journal: JACC Cardiovasc Imaging
DOI: 10.1016/j.jcmg.2020.06.013
sha: 71c5c16456ade0c3e9157569fd43175d5ab2dae7
doc_id: 983346
cord_uid: 44c62200

[Figure: see text]

The COVID-19 pandemic continues to expand in its global impact and has infected nearly 5 million people and has been responsible for over 300,000 deaths worldwide as of May 20th, 2020. While the most profound manifestations of this disease have been due to pulmonary complications, there has been a growing understanding of the devastating cardiac complications of this disease. In early studies from Wuhan, approximately 7% of hospitalized patients with COVID-19 had evidence of increased troponins indicating myocardial involvement, which was associated with worse outcomes.

[1] COVID-19 has been associated with heart failure, acute coronary syndromes, myocarditis and right heart dysfunction. The exact mechanism of cardiac injury in COVID-19 has not been well established, but may involve direct myocyte involvement, or secondary injury from the profound inflammatory response invoked by the virus. [2] With the growing number of infections, we will likely continue to see the impacts of persistent cardiac symptoms in patients infected with COVID-19 for years to come.

Given the typical manifestations of cardiac involvement in COVID-19 namely myocarditis, right heart failure and acute coronary syndromes, CMR would theoretically be the ideal technique for assessing COVID-19 patients with suspected cardiac involvement. CMR is the most accurate cardiovascular imaging technique for diagnosing myocarditis and for differentiating this from acute myocardial infarction, or other etiologies such as stress-induced cardiomyopathy. [3] Furthermore CMR is reference standard technique for quantifying right heart dysfunction. However, in the COVID-19 era, performance of CMR in patients in hospitalized patients with active symptoms has to be weighed against the potential of the exposure of staff and the contamination of scanners, and the likelihood that the information derived from CMR will have an immediate implication for patient management to justify risks.

For these reasons the use of CMR in the acute phase of COVID-19 infections has been limited.

As patients are increasingly recovering from the acute phase of this disease, continued manifestations such as chest pain, heart failure, and palpitations are increasing recognized as ongoing sequelae in the convalescent phase of the disease. To date there has been limited evaluation of the CMR imaging findings in patients with ongoing symptoms that have recovered from the acute disease. Questions regarding the severity of myocardial scarring and ongoing inflammation in patients with persistent cardiac symptoms have not been fully explored with only a few case reports presented.

In the current issue of JACC Cardiovascular Imaging Huang and colleagues [4] describe their initial findings in a retrospective single-center observational study of 26 patients who were diagnosed with COVID-19, had confirmation of recovery following a 14 day isolation and two negative COVID-19 tests, and were subsequently referred to undergo cardiac MRI for assessment of chest discomfort or palpitations. None of these patients had any significant cardiac history or coronary risk factors except a history of hypertension in 2 (8%). A comprehensive CMR evaluation was performed on a 3T scanner including conventional techniques of cine, late gadolinium enhanced imaging (LGE) and T2-weighted short-tau inversion recovery (STIR) imaging, as well as parametric mapping of myocardial T1, T2, and extracellular volume (ECV).

Twenty-two (85%) of the patients had moderate COVID-19 pneumonia and the other 4 had severe pneumonia. None of these patients appeared to have developed symptoms and signs of cardiac failure during their initial treatment to COVID-19 pneumonia. The median time between onset of cardiac symptoms and CMR was 47 days. Only 13 of the 26 patients had hs-cTnI measured during their COVID-19 hospitalization, and all had a normal hs-cTnI at the time of CMR. 14 (54%) of patients had evidence of increased T2 signal ratio by STIR imaging and 31% of cases had evidence of small focal subepicardial and patchy mid-wall LGE in a pattern consistent with myocarditis. Abnormal T2 STIR and LGE were noted to involve 33% and 4% of segments, respectively suggesting significant myocardial edema with minimal scarring. Only one patient, who had positive conventional CMR findings based on T2 STIR and LGE, had an abnormal EF with evidence of a regional wall motion abnormality in the segments with myocardial edema. While the mean LV function was similar among controls and subjects with and without conventional CMR abnormalities, the cohort with conventional CMR findings had reduced RV function as compared to healthy controls. When divided into two groups based on the presence of conventional CMR findings, the group with positive CMR findings had increases in global T1, T2, and ECV compared to those without conventional CMR findings and normal controls. Notably, in the 8 LGE positive patients, the remote myocardium had evidence of increased T1, T2, and ECV as compared to healthy control subjects. These findings suggest presence of mild edema based on the modest magnitude of increase in T1, T2, and ECV respectively (1271 vs 1224 msec, 43 vs 39 msec, and 28.2 vs 23.7%).

The present study is one of the first and largest case series showing that CMR detects abnormal findings in COVID-19 recovered patients who had no evidence of cardiac involvement during their initial treatments, but present subsequently with non-specific cardiac symptoms.

The findings showed globally increased T1, T2, and ECV in patients with conventional CMR abnormalities, even in remote segments, which raises questions regarding ongoing cardiac inflammation and/or fibrosis. Specifically, there appears to be evidence of diffuse myocardial edema based on T2 STIR imaging disproportionate to the small LGE extent, in an absence of LV dysfunction, which begs the question of whether there is direct viral infection or whether cardiac involvement is primarily due to inflammation. These intriguing questions will need to be studied further in larger studies. The current study has a number of limitations. The retrospectively design of the study does not enable assessment of the prevalence of CMR findings in patients that have recovered from acute COVID-19 infections. Secondly the cohort of patients is small, however, this likely reflects the reduction of advanced cardiovascular imaging utilization and resources in a region within the early parts of the epidemic. Larger studies looking at persistent cardiac involvement in COVID-19 will likely follow as advanced cardiovascular imaging services resume more broadly. Interestingly the patients demonstrated evidence of myocardial edema despite absence of hs-TnI positivity, and unfortunately only half of the patients had troponin assessment during their hospitalization.

The strong inflammatory response of COVID-19 could potentially provide therapeutic targets for COVID-19 myocarditis which could necessitate the assessment of COVID-19 myocardial involvement in patient in the acute phase of the disease. There has been particular interest in IL-6, and inhibitors of inflammation could potentially be therapies for COVID-19 myocarditis. As multiple pathologies including acute myocardial infarction, takutsubo cardiomyopathy, and myocarditis are all within the differential diagnosis of a positive troponin, chest pain, and heart failure in COVID-19 patients, a rapid CMR protocol could potentially be used to differentiate between these etiologies. However, performing CMR in these patients necessitates the balance between patient benefit and the need to protecting staff and critical resources.

The present study has important implications regarding the study of COVID-19 related myocarditis, in demonstrating that CMR abnormalities are present and that active inflammation/edema may extend into the sub-acute phase. This may enable the study of myocardial involvement in patients at a time when they have recovered and are lower risk for spreading the disease. Further, determining the etiology for an increased troponin or cardiovascular symptoms could have implications regarding longer term treatment of patients by differentiating evidence of myocardial infarction from myocarditis.

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations